Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Feb;111(2):278-85.
doi: 10.1046/j.1365-2249.1998.00497.x.

Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101

Affiliations

Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101

B Kitze et al. Clin Exp Immunol. 1998 Feb.

Abstract

HTLV-1 causes two distinct human diseases, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T cell leukaemia/lymphoma (ATL). Persistently infected individuals carry a risk of <1% of developing either disease. These basic epidemiological data imply that virus-host interactions, especially immunogenetic factors, influence the outcome of infection. Several studies showed that the HLA class II DR1 DQ5 haplotype is over-represented in HAM/TSP, but rare in ATL. Therefore, we selected four patients with HAM/TSP and one seronegative control who all carried the HLA DR1 DQ5 haplotype. We analysed the CD4+ T lymphocyte response against eight synthetic peptides of HTLV-1 envelope (env) glycoprotein gp21, a crucial target antigen in HAM/TSP. The first of two immunodominant epitopes corresponded to a domain of the HTLV-1 envelope protein which had previously been shown to be essential for HTLV-1 envelope function. The second immunodominant epitope overlapped a highly conserved sequence of the retroviral transmembrane envelope protein. DR1 (DRB1*0101)-restricted T lymphocytes were activated by the conserved peptide sequence in nanomolar concentrations. In contrast, this conserved sequence can also induce non-specific, cAMP-mediated immunosuppressive effects on T cells when added in micromolar concentrations to culture media, as shown by Haraguchi S, Good RA, James-Yarish M, Cianciolo GJ, Day NK, Proc Natl Acad Sci USA 1995; 92:5568-71. Hence, HTLV-1 env gp21 might exert either stimulating immunological or immunosuppressive effects in HTLV-1-infected individuals, depending on the level of its expression and the presence of HLA DRB1*0101.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Inhibition of proliferation by anti-MHC MoAbs. In a representative experiment using T cell line 910/8G7, there was a significant inhibition of antigen-specific proliferation by anti-HLA-DR antibodies (*). Data are expressed as mean + s.d.
Fig. 2
Fig. 2
Proliferation of a HTLV-1 gp21 sp378/sp382-specific CD4+ T cell line (BK/1C11) depending on concentration and amino acid sequences of peptides. (a) Response to two long overlapping synthetic peptides, sp378 and sp382, which were used for selection of T cell lines, and to recombinant HTLV-1 p21. (b) Epitope analysis using short overlapping synthetic peptides with one amino acid shift. Values are expressed as mean + s.d. of triplicated data per point.
Fig. 3
Fig. 3
Analysis of epitope specificity of T cell line BK/2C7 for HTLV-1 gp21 using different overlapping peptides. Only recombinant p21 (rp21), peptides sp400 (amino acids 400–426) and en84 (amino acids 416–430) elicited a strong proliferative response, whereas all other peptides, including peptide sequences 396–410, 401–415, 406–420, 411–425, were negative (for clarity only one negative peptide is shown). Peptide concentrations were 1 μmolll. Data are expressed as mean + s.d.

References

    1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematological features of 16 cases. Blood. 1977;50:481–92. - PubMed
    1. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy. A new clinical entity. Lancet. 1986;1:1031–2. - PubMed
    1. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2:407–10. - PubMed
    1. Usuku K, Sonoda S, Osame M, et al. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Ann Neurol. 1988;23(Suppl.):S143–50. - PubMed
    1. Sonoda S, Yashiki S, Fujiyoshi T, et al. Immunogenetic factors involved in the pathogenesis of adult T-cell leukemia and HTLV-I- associated myelopathy. Gann Monograph Cancer Res. 1992;39:81–93.

Publication types

MeSH terms

Substances